Table 2.
Clinical efficacy of curcumin supplementation in type 2 diabetes
| Study | Study Design | Disease | Trial Size | Study Duration (weeks) | Daily Curcuminoid Intake (mg/day) | Clinical Outcomes in Curcumin Group | Laboratory Outcomes in Curcumin Group |
|---|---|---|---|---|---|---|---|
| 2014 Chuengsamarn [27] | DB, PC, RCT | Diabetes- atherosclerosis | 240 | 24 | 1500 | ↓ abdominal obesity (VF + TBF), Atherogenic risks | ↑ Serum adiponectin ↓ Pulse wave velocity, leptin, Metabolic profile (triglyceride + uric acid) |
| 2014 Na LX [28] | DB, PC, RCT | Diabetes | 100 | 12 | 300 | N/A | ↑ SOD ↓ serum A-FABP, CRP, TNF-a, IL-6 |
| 2012 Na LX [29] | DB, PC, RCT | Diabetes | 100 | 12 | 300 | N/A | ↑ LPL Activity ↓ Fasting blood glucose, HbA1c, HOMA-IR, serum FFAs + triglycerides |
| 2012 Chuengsamarn [30] | DB, PC, RCT | Diabetes | 240 | 36 | 1500 | ↓ T2DM progression | ↑ B-cell function (HOMA-B), adiponectin ↓ C-peptide, HOMA-IR, HbA1c, FPG, OGTT at 2 h |
| 2012 Steigerwalt [31] | PC | Diabetes- microangiopathy | 38 | 4 | 200 | ↑ Improvement in microangiopathy, visual acuity, ↓ Edema score | ↑ Venoarteriolar response |
| 2011 Appendino [32] | PC | Diabetes- microangiopathy | 25 | 4 | 400 | ↑ Improvement in microangiopathy, ↓ Skin Flux, ↓ Edema score | ↑ PO2, Venoarteriolar response |
| 2011 Khajehdehi [33] | DB, PC, RCT | Diabetes-nephropathy | 40 | 12 | 66.3 | N/A | ↓ TGF-B, IL-8, Urinary protein excretion |
| 2008 Usharani [34] | DB, PC, RCT | Diabetes | 72 | 8 | 300 | ↑ Endothelial function | ↓ MDA, ET-1, IL-6, TNF-a |
↑↓ Indicates an increase or decrease in the value of the respective variable. Indicates that no change occurred in that respective variable. A-FABP: Adipokine Adipocyte Fatty Acid-Binding Protein. CRP: C-reactive protein levels. DB: Double-blind. ET-1: Endothelin-1. FFA: Free fatty acids. FPG: Fasting plasma glucose. HBA1C: Hemoglobin A1C. HOMA-B: Homeostatic model assessment for B-cells. HOMA-IR: Homeostatic model assessment for insulin resistance. IL: Interleukin. LPL: Lipoprotein lipase. MDA: Malondialdehyde. OGTT: Oral glucose tolerance test. PC: Placebo controlled. PO2: Partial pressure of oxygen. RCT: Randomized controlled trial. SOD: Superoxide dismutase. TBF: Total body fat. TGF-B: Transforming growth factor beta 1. TNF-A: Tumor necrosis factor alpha. VF: Ventricular fibrillation.